|   | |||||
| 
 | 
|  | |
|  | |
|  | |
|  | |
|  | |
|  | |
|  | 
| Gene: SND1 | 
| Gene summary for SND1 | 
|  Gene summary. | 
| Gene information | Species | Human | Gene symbol | SND1 | Gene ID | 27044 | 
| Gene name | staphylococcal nuclease and tudor domain containing 1 | |
| Gene Alias | TDRD11 | |
| Cytomap | 7q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | A0A140VK49 | 
| Top | 
| Malignant transformation analysis | 
|  Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells | 
|  Malignant transformation involving gene list. | 
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy | 
| 27044 | SND1 | CCI_2 | Human | Cervix | CC | 8.64e-03 | 6.55e-01 | 0.5249 | 
| 27044 | SND1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.28e-06 | 6.99e-01 | -0.059 | 
| 27044 | SND1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.80e-04 | 4.55e-01 | 0.294 | 
| 27044 | SND1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 6.61e-24 | 1.46e+00 | 0.3487 | 
| 27044 | SND1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.76e-18 | 1.15e+00 | 0.281 | 
| 27044 | SND1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 9.93e-23 | 1.21e+00 | 0.3859 | 
| 27044 | SND1 | A015-C-203 | Human | Colorectum | FAP | 1.12e-35 | -5.97e-01 | -0.1294 | 
| 27044 | SND1 | A015-C-204 | Human | Colorectum | FAP | 9.28e-09 | -3.57e-01 | -0.0228 | 
| 27044 | SND1 | A014-C-040 | Human | Colorectum | FAP | 9.61e-06 | -5.01e-01 | -0.1184 | 
| 27044 | SND1 | A002-C-201 | Human | Colorectum | FAP | 2.28e-14 | -3.46e-01 | 0.0324 | 
| 27044 | SND1 | A001-C-119 | Human | Colorectum | FAP | 4.93e-18 | -7.17e-01 | -0.1557 | 
| 27044 | SND1 | A001-C-108 | Human | Colorectum | FAP | 3.74e-21 | -5.22e-01 | -0.0272 | 
| 27044 | SND1 | A002-C-205 | Human | Colorectum | FAP | 9.20e-32 | -5.91e-01 | -0.1236 | 
| 27044 | SND1 | A001-C-104 | Human | Colorectum | FAP | 1.07e-03 | -3.51e-01 | 0.0184 | 
| 27044 | SND1 | A015-C-005 | Human | Colorectum | FAP | 1.04e-05 | -3.44e-01 | -0.0336 | 
| 27044 | SND1 | A015-C-006 | Human | Colorectum | FAP | 1.96e-20 | -5.21e-01 | -0.0994 | 
| 27044 | SND1 | A015-C-106 | Human | Colorectum | FAP | 1.30e-17 | -3.92e-01 | -0.0511 | 
| 27044 | SND1 | A002-C-114 | Human | Colorectum | FAP | 8.47e-29 | -6.87e-01 | -0.1561 | 
| 27044 | SND1 | A015-C-104 | Human | Colorectum | FAP | 7.76e-40 | -6.97e-01 | -0.1899 | 
| 27044 | SND1 | A001-C-014 | Human | Colorectum | FAP | 7.20e-19 | -4.33e-01 | 0.0135 | 
| Page: 1 2 3 4 5 6 7 8 9 10 11 | 
|  Transcriptomic changes along malignancy continuum. | 
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. | 
| Top | 
| Malignant transformation related pathway analysis | 
|  Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer | 
|  Figure of enriched GO biological processes. | 
| Tissue | Disease Stage | Enriched GO biological Processes | 
| Colorectum | AD |  | 
| Colorectum | SER |  | 
| Colorectum | MSS |  | 
| Colorectum | MSI-H |  | 
| Colorectum | FAP |  | 
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). | 
| Page: 1 2 3 4 5 6 7 8 9 | 
|  Enriched GO biological processes. | 
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count | 
| GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 | 
| GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 | 
| GO:00016497 | Cervix | CC | osteoblast differentiation | 47/2311 | 229/18723 | 2.88e-04 | 3.11e-03 | 47 | 
| GO:00467008 | Cervix | CC | heterocycle catabolic process | 80/2311 | 445/18723 | 3.23e-04 | 3.42e-03 | 80 | 
| GO:00346559 | Cervix | CC | nucleobase-containing compound catabolic process | 74/2311 | 407/18723 | 3.77e-04 | 3.88e-03 | 74 | 
| GO:00442709 | Cervix | CC | cellular nitrogen compound catabolic process | 79/2311 | 451/18723 | 7.80e-04 | 6.91e-03 | 79 | 
| GO:00015037 | Cervix | CC | ossification | 71/2311 | 408/18723 | 1.67e-03 | 1.28e-02 | 71 | 
| GO:00194398 | Cervix | CC | aromatic compound catabolic process | 79/2311 | 467/18723 | 2.14e-03 | 1.54e-02 | 79 | 
| GO:19013618 | Cervix | CC | organic cyclic compound catabolic process | 80/2311 | 495/18723 | 6.77e-03 | 3.72e-02 | 80 | 
| GO:0006401 | Colorectum | AD | RNA catabolic process | 102/3918 | 278/18723 | 8.64e-10 | 6.76e-08 | 102 | 
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 | 
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 | 
| GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 | 
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 | 
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 | 
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 | 
| GO:0001649 | Colorectum | AD | osteoblast differentiation | 70/3918 | 229/18723 | 3.59e-04 | 4.18e-03 | 70 | 
| GO:0001503 | Colorectum | AD | ossification | 106/3918 | 408/18723 | 7.68e-03 | 4.64e-02 | 106 | 
| GO:00064012 | Colorectum | MSS | RNA catabolic process | 102/3467 | 278/18723 | 5.07e-13 | 1.02e-10 | 102 | 
| GO:00064022 | Colorectum | MSS | mRNA catabolic process | 89/3467 | 232/18723 | 8.70e-13 | 1.60e-10 | 89 | 
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 | 
|  Enriched KEGG pathways. | 
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count | 
| hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 | 
| hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 | 
| hsa05203 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 | 
| hsa052031 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 | 
| hsa052032 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 | 
| hsa052033 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 | 
| hsa052034 | Lung | IAC | Viral carcinogenesis | 43/1053 | 204/8465 | 3.02e-04 | 3.07e-03 | 2.04e-03 | 43 | 
| hsa0520311 | Lung | IAC | Viral carcinogenesis | 43/1053 | 204/8465 | 3.02e-04 | 3.07e-03 | 2.04e-03 | 43 | 
| hsa0520321 | Lung | AIS | Viral carcinogenesis | 37/961 | 204/8465 | 2.49e-03 | 1.49e-02 | 9.55e-03 | 37 | 
| hsa0520331 | Lung | AIS | Viral carcinogenesis | 37/961 | 204/8465 | 2.49e-03 | 1.49e-02 | 9.55e-03 | 37 | 
| hsa052038 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 | 
| hsa0520314 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 | 
| hsa0520324 | Oral cavity | LP | Viral carcinogenesis | 90/2418 | 204/8465 | 1.20e-06 | 1.38e-05 | 8.89e-06 | 90 | 
| hsa0520334 | Oral cavity | LP | Viral carcinogenesis | 90/2418 | 204/8465 | 1.20e-06 | 1.38e-05 | 8.89e-06 | 90 | 
| hsa0520342 | Oral cavity | EOLP | Viral carcinogenesis | 55/1218 | 204/8465 | 1.54e-06 | 1.34e-05 | 7.92e-06 | 55 | 
| hsa0520351 | Oral cavity | EOLP | Viral carcinogenesis | 55/1218 | 204/8465 | 1.54e-06 | 1.34e-05 | 7.92e-06 | 55 | 
| hsa0520361 | Oral cavity | NEOLP | Viral carcinogenesis | 56/1112 | 204/8465 | 2.90e-08 | 5.34e-07 | 3.36e-07 | 56 | 
| hsa0520371 | Oral cavity | NEOLP | Viral carcinogenesis | 56/1112 | 204/8465 | 2.90e-08 | 5.34e-07 | 3.36e-07 | 56 | 
| hsa052037 | Prostate | BPH | Viral carcinogenesis | 69/1718 | 204/8465 | 3.40e-06 | 2.87e-05 | 1.78e-05 | 69 | 
| hsa0520313 | Prostate | BPH | Viral carcinogenesis | 69/1718 | 204/8465 | 3.40e-06 | 2.87e-05 | 1.78e-05 | 69 | 
| Page: 1 2 | 
| Top | 
| Cell-cell communication analysis | 
|  Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states | 
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage | 
| Page: 1 | 
| Top | 
| Single-cell gene regulatory network inference analysis | 
|  Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states | 
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity | 
| SND1 | TREG | Esophagus | ADJ | LINC00324,ZNF292,MBLAC2, etc. | 3.19e-02 |  | 
| SND1 | TREG | Esophagus | ESCC | LINC00324,ZNF292,MBLAC2, etc. | 1.33e-01 |  | 
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. | 
| Page: 1 | 
| Top | 
| Somatic mutation of malignant transformation related genes | 
|  Annotation of somatic variants for genes involved in malignant transformation | 
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome | 
| SND1 | SNV | Missense_Mutation | c.2662N>T | p.Ala888Ser | p.A888S | Q7KZF4 | protein_coding | tolerated(0.8) | benign(0.013) | TCGA-A2-A0ST-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SND1 | SNV | Missense_Mutation | c.2149N>T | p.Asp717Tyr | p.D717Y | Q7KZF4 | protein_coding | deleterious(0.04) | possibly_damaging(0.686) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| SND1 | SNV | Missense_Mutation | c.829N>G | p.Ile277Val | p.I277V | Q7KZF4 | protein_coding | tolerated(0.38) | benign(0.074) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| SND1 | deletion | Frame_Shift_Del | c.752delT | p.Phe251SerfsTer39 | p.F251Sfs*39 | Q7KZF4 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| SND1 | insertion | In_Frame_Ins | novel | c.2711_2712insTCATTCCTTTTTATGGCTAAGGGAGAGCTCTGG | p.Asp904_Glu905insHisSerPheLeuTrpLeuArgGluSerSerGly | p.D904_E905insHSFLWLRESSG | Q7KZF4 | protein_coding | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| SND1 | insertion | Frame_Shift_Ins | novel | c.2713_2714insCTTACCT | p.Glu905AlafsTer42 | p.E905Afs*42 | Q7KZF4 | protein_coding | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| SND1 | SNV | Missense_Mutation | novel | c.2060T>G | p.Val687Gly | p.V687G | Q7KZF4 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | 
| SND1 | SNV | Missense_Mutation | c.241N>G | p.Pro81Ala | p.P81A | Q7KZF4 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| SND1 | SNV | Missense_Mutation | c.112N>G | p.Gln38Glu | p.Q38E | Q7KZF4 | protein_coding | tolerated(0.11) | benign(0.222) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SND1 | SNV | Missense_Mutation | c.835N>T | p.His279Tyr | p.H279Y | Q7KZF4 | protein_coding | deleterious(0.04) | possibly_damaging(0.737) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | 
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 | 
| Top | 
| Related drugs of malignant transformation related genes | 
|  Identification of chemicals and drugs interact with genes involved in malignant transfromation | 
| (DGIdb 4.0) | 
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs | 
| Page: 1 |